AHB(SH:688639) Zheng Quan Zhi Xing·2025-09-04 16:18Core Viewpoint - Anhui Huaheng Biological Technology Co., Ltd. plans to issue H shares and list on the Hong Kong Stock Exchange to enhance its global development strategy, brand influence, and core competitiveness [1][2]. Meeting Details - The 18th meeting of the 4th Supervisory Board was held on September 4, 2025, with all three supervisors present, complying with relevant laws and regulations [1]. H Share Issuance Proposal - The Supervisory Board approved the proposal for issuing H shares and listing on the Hong Kong Stock Exchange, aiming to optimize capital structure and broaden financing channels [2][3]. - The H shares will be ordinary shares with a par value of RMB 1, issued in foreign currency [2]. Issuance and Listing Plan - The issuance will include both public offerings in Hong Kong and international placements, with the total number of H shares not exceeding 15% of the company's total share capital post-issuance [3][4]. - The final issuance price will be determined based on market conditions and investor demand [4]. Fund Utilization Plan - The funds raised from the H share issuance will be used for global expansion, new product development, capacity upgrades, and general corporate purposes [8][9]. Transition to Overseas Listed Company - Following the H share issuance, the company will transition to an overseas listed public company, listed on both the Shanghai Stock Exchange and the Hong Kong Stock Exchange [9]. Audit and Professional Services - The Supervisory Board approved the appointment of Yongcheng (Hong Kong) CPA Limited as the auditing firm for the H share issuance [10]. Governance Changes - The company plans to abolish the Supervisory Board and amend its Articles of Association to align with the latest legal requirements and improve governance structure [11].